Retatrutide vs NAD+ (Nicotinamide Adenine Dinucleotide)

Retatrutide and NAD+ (Nicotinamide Adenine Dinucleotide) are both investigated for metabolic health, but they operate through fundamentally different biological pathways. Retatrutide is an investigational peptide that targets GIP, GLP-1, and glucagon receptors, with Phase 2 and Phase 3 trials demonstrating substantial weight reduction and glycemic improvements. In contrast, NAD+ is a ubiquitous coenzyme involved in cellular energy metabolism and signaling, with research focusing on its decline with age and potential for restoration via precursors. While Retatrutide’s evidence base is dominated by large-scale clinical trials, NAD+ research relies heavily on mechanistic studies and smaller human interventions. This comparison highlights the divergent evidence levels, mechanisms, and research priorities for each compound.

Retatrutide is a first-in-class triple agonist developed by Eli Lilly, simultaneously activating GIP, GLP-1, and glucagon receptors. This design aims to enhance energy expenditure and appetite suppression beyond dual agonists. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved a mean 24.2% body weight reduction at 48 weeks, with 100% of participants losing at least 5% of baseline weight. Phase 3 TRIUMPH trials are ongoing; TRIUMPH-4 (Dec 2025) reported average weight loss up to 71.2 lbs alongside osteoarthritis pain relief. Expected FDA approval is 2027–2028. Evidence is strongest for weight management and glycemic control in type 2 diabetes, with a clear dose-response relationship.

NAD+ is a fundamental coenzyme present in all living cells, serving as a critical electron carrier in redox reactions and as a substrate for sirtuins, PARPs, and CD38. Research indicates that NAD+ levels decline approximately 50% between ages 40 and 60, which is hypothesized to contribute to metabolic and aging-related decline. While not a peptide, NAD+ and its precursors (NMN, NR) are frequently discussed in peptide research communities. IV NAD+ infusions are used in anti-aging clinics, but large-scale human efficacy trials are limited. Preclinical studies suggest roles in mitochondrial function and DNA repair, but human evidence for longevity or metabolic benefits remains preliminary and inconsistent.

Both Retatrutide and NAD+ are studied for metabolic health, though their focus areas diverge. Retatrutide is primarily investigated for weight management, with clinical trials demonstrating robust effects on body weight and glycemic control. NAD+ research extends to anti-aging and longevity, with studies exploring its role in cellular energy metabolism, mitochondrial function, and age-related decline. While Retatrutide’s metabolic effects are acute and dose-dependent, NAD+ research often targets chronic, low-grade metabolic dysfunction associated with aging. Researchers should note that the evidence for Retatrutide in metabolic health is far more advanced, with Phase 3 data, whereas NAD+ remains largely in preclinical or early clinical stages for these applications.

Retatrutide safety data from clinical trials show dose-related gastrointestinal side effects (13–63% across dose groups), including nausea, vomiting, diarrhea, and constipation. These events are mostly mild to moderate and partially mitigated by a lower starting dose (2 mg vs. 4 mg). Dose-dependent heart rate increases peak at 24 weeks and decline thereafter. For NAD+, IV administration commonly causes flushing, nausea, chest tightness, and abdominal cramping, which are dose-rate dependent. Rare tachycardia and blood pressure changes occur during IV infusion. Oral precursors like NMN and NR are generally well-tolerated at doses up to 1200 mg/day. The safety profiles reflect different administration routes and mechanisms, with Retatrutide’s effects being more predictable and dose-dependent.